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Abstract
Background: APE1 (apurinic/apyrimidinic endonuclease 1) is an important DNA repair protein in the base excision
repair pathway. Polymorphisms in APE1 have been implicated in susceptibility to cancer; however, results from the
published studies remained inconclusive. The objective of this study was to conduct a meta-analysis investigating
the association between polymorphisms in APE1 and the risk for cancer.
Methods: The PubMed and Embase databases were searched for case-control studies published up to June, 2011
that investigated APE1 polymorphisms and cancer risk. Odds ratios (ORs) and 95% confidence intervals (CIs) were
used to assess the strength of the associations.
Results: Two polymorphisms (−656 T > G, rs1760944 and 1349 T > G, rs1130409) in 37 case-control studies
including 15, 544 cancer cases and 21, 109 controls were analyzed. Overall, variant genotypes (GG and TG/GG) of
−656 T > G polymorphism were associated with significantly decreased cancer risk in homozygote comparison (OR
= 0.81, 95%CI: 0.67-0.97), dominant model comparison (OR = 0.89, 95%CI: 0.81-0.97) and recessive model
comparison (OR = 0.90, 95%CI: 0.82-0.98), whereas the 1349 T > G polymorphism had no effects on overall cancer
risk. In the stratified analyses for −656 T > G polymorphism, there was a significantly decreased risk of lung cancer
and among Asian populations.
Conclusions: Although some modest bias could not be eliminated, the meta-analysis suggests that APE1 −656 T >
G polymorphism has a possible protective effect on cancer risk particularly among Asian populations whereas 1349
T > G polymorphism does not contribute to the development of cancer.
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Background
Cancer is a multifactor disease caused by complex inter-
actions between environmental and genetic factors [1].
The incidence of different cancer varies widely in differ-
ent populations which may be largely attributed to life-
style and genetic background [2]. Environmental factors
such as smoking and exposure to carcinogens lead to
direct damage to DNA [3]. To a certain extent, these
damages can be repaired by endogenous DNA repair
systems [4]. However, genetic variations in these systems
may result in reduced repair capability and the defect
allow DNA damage to accumulate which leads to per-
manent mutations in the genome and contributes to
carcinogenesis.
Among DNA repair systems, base excision repair
(BER) pathway is responsible for repairing small lesions
such as oxidative damage, alkylation, or methylation [5].
AP Endonuclease 1 (APE1, also known as APE, APEX,
HAP1, and REF-1) is a multifunctional protein and
plays a central role in the BER pathway through hydro-
lyzing the phosphodiester backbone immediately 5’ to
the AP site [5,6]. APE1 can act as a 3’-phosphodiester-
ase to initiate repair of DNA single strand breaks, which
are produced either directly by reactive oxygen species
or indirectly through the enzymatic removal of damaged
bases [7,8]. APE1 is also known as a transcriptional
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in cancer development [9] and is considered as a pro-
mising tool for anticancer therapy [10].
The human APE1 is located on chromosome 14q11.2-
q12 and consists of five Exons spanning 2.21 kb [11].
Till now, many epidemiological studies suggested
genetic variations in APE1 may confer individuals’ sus-
ceptibility to cancer. A total of 18 single nucleotide
polymorphisms (SNPs) in APE1 have been identified
[11], of which, two functional SNPs (−656 T > G in the
promoter region, rs1760944 and 1349 T > G in the fifth
Exon, rs1130409) have been wildly investigated. In lung
cancer, Lu et al. and Lo et al. reported that −656 T > G
polymorphism influenced the transcriptional activity of
APE1 and contributed to lung cancer susceptibility
[12,13]. Although one study in bladder cancer supported
the association [14], it has not been replicated in some
others [15-17]. As to 1349 T > G polymorphism, func-
tional studies suggested that the G allele may have
altered endonuclease and DNA-binding activity, reduced
ability to communicate with other BER proteins and
decreased capacity to repair DNA oxidative damage
[18,19]. Recently, numerous studies investigated the
influence of 1349 T > G polymorphism on cancer risk;
however, the results of these studies remain
inconclusive.
To reveal a small effect of the polymorphisms on can-
cer risk, a single study might be underpowered, particu-
larly for studies with relatively small sample size. Meta-
analysis is a statistical technique for combining results
from different studies to produce a single estimate of
the major effect with enhanced precision. It is consid-
ered a powerful tool to summarize inconclusive results
from different studies. To clarify the effect of the APE1
-656 T > G and 1349 T > G polymorphisms on cancer
risk; we conducted a meta-analysis of all eligible case-
control studies that have been published. Before analy-
sis, we tested whether these two SNPs were in linkage
disequilibrium with each other in Europeans and Asians,
and the data from HapMap database suggested the two
SNPs were not correlated (D’ = 0.335, r
2 =0 . 0 7 1f o r
Europeans and D’ = 0.409, r
2 = 0.071 for Asians).
Methods
Identification of eligible studies
A literature search of the PubMed and EMBASE data-
bases (updated to June, 2011) was conducted using com-
binations of the following terms: “APE1”, “APEX”,
“HAP1”, “REF-1”, “polymorphism”,a n d“cancer”.T h e
search was limited to English language papers. All stu-
dies that evaluated the association between polymorph-
isms of APE1 and cancer risk were retrieved, and their
bibliographies were checked for other relevant publica-
tions. Studies that were included in the meta-analysis
had to meet all of the following criteria: 1) evaluate the
APE1 −656T > G and 1349T > G polymorphisms and
cancer risk, 2) use a case-control design, 3) contain
available genotypes frequency for estimating an odds
ratio (OR) with a 95% confidence intervals (CIs), 4) gen-
otype distributions in control consistent with Hardy-
Weinberg equilibrium (HWE). Accordingly, abstracts
a n dr e v i e w ss t u d i e st h a tt h a td i dn o tr e p o r tg e n o t y p e
frequency were excluded. When more than one of the
same patient population was included in several publica-
tions, only the most recent or complete study was used
in this meta-analysis.
Data extraction
Information was carefully extracted from all eligible
publications independently by two of the authors
according to the selection criteria. In case of disagree-
ment, a third reviewer assessed the articles. The follow-
ing items were collected: author name, year of
publication, country of origin, ethnicity, source of the
controls, genotyping method, cancer type, total number
of cases and controls, and genotype distributions in
cases and controls.
Statistical analysis
The strength of associations between APE1 polymorph-
isms and cancer risk were measured by ORs with 95%
CIs. We examined the association between the APE1
−656 T > G and 1349 T > G polymorphisms and cancer
risk in homozygote comparison (GG vs. TT), heterozy-
gote comparison (TG vs. TT), the dominant genetic
model (TG/GG vs. TT), and the recessive genetic model
(GG vs. TT/TG). Stratified analyses were also carried
out by ethnicity, cancer type and source of controls.
Heterogeneity assumption was evaluated with a chi-
square-based Q-test. If the P value is greater than 0.05
of the Q-test, which indicates a lack of heterogeneity
among studies, the summary OR estimate of each study
was calculated by a fixed effects model (the Mantel-
Haenszel method) [20]; otherwise, the random-effects
model (the DerSimoniane and Laird method) [21] was
performed. Sensitivity analyses were also performed to
assess the stability of the results. Funnel plots and
Egger’s linear regression test were used to provide diag-
nosis of the potential publication bias. All statistical ana-
l y s i sw e r ed o n ew i t ht h eS t a t as o f t w a r e( v e r s i o n1 1 . 0 ;
StataCorp LP, College Station, TX), using two-sided P
values.
Results
Study selection and characteristics in the meta-analysis
A total of 37 eligible studies from 32 articles met the
inclusion criteria [12-17,22-47]. In total, 5,139 cases and
5,201 controls from 8 studies for −656 T > G
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Page 2 of 9polymorphism [12-17], and 14,222 cases and 19,746
controls from 35 studies for 1349 T > G polymorphism
were included in the pooled analyses
[12-14,16,17,22-47]. The characteristics of selected stu-
dies are presented in Table 1. The distribution of geno-
types in the controls of all studies was consistent with
HWE. Of the 8 studies for −656 T > G polymorphism,
3 investigated lung cancer and 2 investigated bladder
cancer, and the other 3 articles investigated individually
brain cancer, renal cell cancer and colorectal adenoma.
Six of these studies were conducted in Asian popula-
tions and 2 in European populations. Among the 35 stu-
dies for 1349 T > G polymorphism, there were 7
bladder cancer studies, 4 breast cancer studies, 4 color-
ectal cancer studies, 2 head and neck cancer studies, 9
lung cancer studies and 9 others studies including oeso-
phageal cancer, pancreatic cancer, leukaemia, prostate
cancer, biliary tract cancer, thyroid cancer, renal cell
cancer and gastric cancer. Ten of these studies were
from Asians, 23 were from Europeans and 2 were stu-
dies of mixed populations.
The −656 T > G polymorphism
The frequency of the G allele varied widely across the 8
studies, ranging from 0.44 to 0.64. The average fre-
quency of the G allele in Asian populations was 0.45,
which was lower than that in European populations
(0.62). The difference was statistical significant (P <
0.001).
Overall, there was evidence of an association between
decreased cancer risk and the variant genotypes in dif-
ferent genetic models when all the eligible studies were
pooled into the meta-analysis. As show in Table 2, com-
pared with the wild-type homozygote genotype, the
homozygote variant genotype GG was associated with a
statistically significant decreased risk of all types of can-
cer (OR = 0.81, 95%CI = 0.67-0.97). Besides, significant
main effects were also observed both in dominant and
recessive models (OR = 0.89, 95%CI = 0.81-0.97 and OR
= 0.90, 95%CI = 0.82-0.98). In the stratified analysis by
populations, as shown in Table 2 and Figure 1, the effect
was remain in studies of Asian populations (homozygote
comparison: OR = 0.75, 95%CI = 0.65-0.86; heterozygote
comparison: OR = 0.89, 95%CI = 0.80-0.99; dominant
model: OR = 0.85, 95%CI = 0.77-0.94 and recessive
model: OR = 0.81, 95%CI = 0.71-0.91). In the stratified
analysis by cancer type, as shown in Table 2 and Figure
2, the effect was remain in lung cancer studies (homozy-
gote comparison: OR = 0.65, 95%CI = 0.54-0.79; hetero-
zygote comparison: OR = 0.83, 95%CI = 0.72-0.97;
dominant model: OR = 0.78, 95%CI = 0.68-0.89 and
recessive model: OR = 0.72, 95%CI = 0.61-0.86). Further
subgroup analyses were not performed because of lim-
ited data for this polymorphism.
Heterogeneity was observed in homozygote compari-
son (P heterogeneity = 0.015) for the main effects. There-
fore, we conducted sensitivity analyses to locate the
source of heterogeneity, and the results suggested that
two studies [16,47] were the main origin of the hetero-
geneity. The heterogeneity was effectively removed after
exclusion of these studies (P heterogeneity = 0.123, 0.355
and 0.163, respectively for homozygote comparison,
dominant and recessive model). The results were not
materially altered after exclusion of these studies, sug-
gesting the results of this meta-analysis were stable.
As shown in Figure 3, the shape of the funnel plots
seemed asymmetrical in the recessive model, suggesting
the presence of publication bias. The Egger’st e s t
showed obvious evidence of publication bias (t = −3.01,
P = 0.024, recessive model). To adjust for this bias, a
trim-and-fill method developed by Duval and Tweedie
[48] was conducted, the adjusted estimates obtained by
using random-effects model was OR of 0.87 (0.76-0.99).
Meta-analysis with or without the trim-and-fill method
did not draw different conclusions, indicating that our
results were statistically robust.
The 1349 T > G polymorphism
The frequency of the G allele varied widely across the
39 studies, ranging from 0.20 to 0.52. However, no sig-
nificant difference in the frequency distribution of the G
allele between Asian and European populations were
observed (frequencies of G allele were 0.42 and 0.44 in
Asian and European populations, respectively; P =
0.514).
As shown in Table 3, the results did not suggest any
statistical evidence of an association between the 1349 T
> G polymorphism and overall cancer risk (Table 3). In
the subgroup analysis by ethnicities, source of controls
and cancer types, still no significant association was
observed (Table 3). No publication bias was detected by
either the funnel plot or the Egger test (GG vs. TT: t =
0.33, P = 0.745; TG vs.TT: t = 1.22, P =0 . 2 3 3 ;T G / G G
vs. TT: t = 1.29, P = 0.244; GG vs. TT/TG: t = 0.02, P =
0.985).
Discussion
To data, numerous studies have been carried out to
investigate whether polymorphisms in APE1 are asso-
ciated with the risk of cancer; however, the data have
yielded conflicting results. In the present study, to derive
a more precise estimation of the relationship, we per-
formed a meta-analysis of 37 published studies including
5,139 cases and 5,201 controls for APE1 −656 T > G
polymorphism, and 14,222 cases and 19,746 controls for
APE1 1349 T > G polymorphism. Our meta-analysis
indicated that variant genotypes (GG and TG/GG) of
−656 T > G polymorphism was associated with a
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Study Country Ethnicity Cancer type Sample size case/
control
Source of
controls
Genotyping method Polymorphisms
Misra 2003
20 Finland European Lung cancer 310/302 Population TaqMan 1349 T > G
Popanda 2004
21
Germany European Lung cancer 459/457 Hospital Rapid capillary PCR 1349 T > G
Hao 2004
22 China Asian Oesophageal
cancer
409/478 Population PCR-RFLP 1349 T > G
Ito 2004
23 Japan Asian Lung cancer 178/449 Hospital PCR-RFLP 1349 T > G
Shen 2005
24 China Asian Lung cancer 117/113 Population TaqMan 1349 T > G
Moreno 2006
25
Spain European Colorectal cancer 359/312 Hospital Arrayed primer
extension
1349 T > G
Jiao 2006
26 USA European Pancreatic cancer 367/330 Hospital Allele-specific PCR 1349 T > G
Terry 2006
27 USA European Bladder cancer 229/207 Hospital MALDI-TOF 1349 T > G
Wu 2006
28 USA European Bladder cancer 596/590 Hospital TaqMan 1349 T > G
Zhang 2006
29 USA European Breast cancer 1529/1207 Population TaqMan 1349 T > G
Matullo 2006
30
Multi-
country
European Breast cancer 124/1094 Population TaqMan 1349 T > G
Lung cancer 116/1094 Population TaqMan 1349 T > G
Head and neck
cancer
82/1094 Population TaqMan 1349 T > G
Leukemia 169/1094 Population TaqMan 1349 T > G
Chen 2006
31 USA Mixed Prostate cancer 351/329 Hospital PCR-RFLP 1349 T > G
Li 2007
32 USA European Head and neck
cancer
830/854 Hospital PCR-RFLP 1349 T > G
Berndt 2007
14
USA European Colorectal cancer 767/773 Population TaqMan 1349 T > G, −656 T
>G
Figueroa 2007
15
Spain European Bladder cancer 1150/1149 Hospital TaqMan 1349 T > G, −656 T
>G
Andrew 2008
33
USA/Italy European Bladder cancer 911/1165 Population SNP mass-tagging
system
1349 T > G
Pardini 2008
34
Czech European Colorectal cancer 531/530 Hospital TaqMan 1349 T > G
Mitra 2008
35 India European Bladder cancer 150/225 Population PCR-RFLP 1349 T > G
Tse 2008
36 USA European Colorectal cancer 311/454 Hospital TaqMan 1349 T > G
Huang 2008
37
China Asian Biliary tract cancer 409/783 Population TaqMan 1349 T > G
Chiang 2008
38
China Asian Thyroid cancer 283/469 Hospital TaqMan 1349 T > G
Smith 2008
39 USA Asian Breast cancer 372/480 Hospital Arrayed primer
extension
1349 T > G
Gangwar 2009
40
India European Bladder cancer 206/250 Hospital TaqMan 1349 T > G
Agachan 2009
41
Turkey European Lung cancer 98/67 Hospital PCR-RFLP 1349 T > G
Lo 2009
11 China Asian Lung cancer 729/722 Hospital Arrayed primer
extension
1349 T > G, −656 T
>G
Lu 2009
10 China Asian Lung cancer 500/517 Population Illumina 1349 T > G, −656 T
>G
Lung cancer 572/547 Hospital SNPscan −656 T > G
Wang 2010
12 China Asian Bladder cancer 234/253 Hospital PCR-RFLP 1349 T > G, -656 T
>G
Deng 2010
42 China Asian Lung cancer 315/314 Population RT-PCR 1349 T > G
Palli 2010
43 Italy European Gastric cancer 298/546 Population TaqMan 1349 T > G
Zhou et al. BMC Cancer 2011, 11:521
http://www.biomedcentral.com/1471-2407/11/521
Page 4 of 9significant decrease in the overall risk of cancer, espe-
cially for lung cancer and Asians. However, the 1349 T
> G polymorphism did not appear to have significant
influence on the overall risk of cancer.
Apurinic/apyrimidinic (AP) sites are common muta-
genic and cytotoxic DNA lesions which caused by the
loss of normal bases [49]. APE1 had been extensively
studied as the major AP endonuclease involved in the
repair of AP sites through both its endonuclease and
phosphodiesterase activities [7]. Alteration in the expres-
sion of APE1 may influence its capacity to repair DNA
damage. Several lines of evidence support that the −656
T > G polymorphism plays a role in influencing the pro-
moter activity of APE1. Using in vitro promoter assay,
Lo et al. found that the −656 G allele had a significantly
higher transcriptional activity than that of the −656 T
allele and individuals with the −656 G allele were at a
decreased risk for lung cancer [13]. In their view, the
“higher production” genotype for APE1 might offer pro-
tection against the development of lung cancer [13].
Nearly at the same time, Lu et al. also reported a similar
protective effect of the −656 G allele against lung cancer
risk in two independent studies [12]. However, they
showed that the G allele attenuated the binding of Oct-
1 to the promoter region of APE1 a n dr e s u l t e di n
decreased transcriptional activity. Given the disparity
between these functional studies, the mechanism under-
lying the regulation of APE1 by this polymorphism may
be still required further investigation. Nevertheless, our
meta-analysis showed that individuals with the variant
genotypes (GG or GG/TG) of −656 T > G polymorph-
ism were associated with a decreased cancer risk than
those with the TT genotype. Although publication bias
was observed in the recessive genetic model, our meta-
analysis with or without trim-and-fill method did not
draw different conclusions, suggesting that our results
were statistically robust.
In the subgroup analysis by cancer type, we found that
individuals with the variant genotypes of −656 T > G
polymorphism were associated with decreased lung can-
cer risk. However, the result should be interpreted with
caution. Because, only four types of cancer (lung cancer,
bladder cancer, brain tumor and colorectal adenoma)
were included and the studies of each type were very
limited, which may have insufficient power to reveal a
reliable association. In the subgroup analysis by ethni-
city, the results suggested that the association was more
apparent among Asian populations. Several reasons may
lead to the ethnic difference. First, differences in genetic
background may cause the difference. Then, environ-
mental or life style context which strongly vary between
populations may play a role. Besides, other factors such
as selection bias and different matching criteria may
also result in the difference. In considering of the lim-
ited numbers of studies, in the future, large numbers of
studies will be required to validate these associations.
Table 1 Characteristics of populations and cancer types of the studies included in the meta-analysis (Continued)
Jelonek 2010
44
Poland European Colorectal cancer 113/153 Hospital PCR-RFLP 1349 T > G
Breast cancer 91/412 Hospital PCR-RFLP 1349 T > G
Zhou 2011
13 China Asian Brain cancer 750/816 Hospital MassARRAY −656 T > G
Cao 2011
45 China Asian Renal cell
carcinoma
612/632 Hospital TaqMan 1349 T > G, -656 T
>G
RFLP, restriction fragment length polymorphism; PCR, polymerase chain reaction; MALDI-TOF, matrix assisted laser desorption/ionization time-of-flight; SNP, single
nucleotide polymorphism; C, cytosine; T, thymine; PCR-CTPP, polymerase chain reaction with confronting two-pair primers.
Table 2 Meta-analysis of the APE1 −656 T > G polymorphism and cancer risk
Variables n * GG vs. TT TG vs. TT GG/TG vs. TT GG vs. TT/TG
OR (95% CI)
† P
‡ OR (95% CI)
† P
‡ OR (95% CI)
† P
‡ OR (95% CI)
† P
‡
Total 8 0.81 (0.67-0.97) 0.015 0.92 (0.83-1.01) 0.340 0.89 (0.81-0.97) 0.084 0.90 (0.82-0.98) 0.059
Ethnicities
Asian 6 0.75 (0.65-0.86) 0.057 0.89 (0.80-0.99) 0.255 0.85 (0.77-0.94) 0.093 0.81(0.71-0.91) 0.252
European 2 1.04 (0.85-1.28) 0.703 1.01 (0.83-1.24) 0.692 1.03 (0.85-1.24) 0.680 1.03 (0.90-1.18) 0.891
Cancer types
Lung cancer 3 0.65 (0.54-0.79) 0.857 0.83 (0.72-0.97) 0.469 0.78 (0.68-0.89) 0.602 0.72 (0.61-0.86) 0.799
Bladder cancer 2 0.88 (0.70-1.12) 0.045 0.89 (0.72-1.11) 0.583 0.88 (0.71-1.08) 0.097 0.97 (0.82-1.14) 0.086
Others 3 1.00 (0.83-1.19) 0.276 1.03 (0.88-1.19) 0.340 1.02 (0.88-1.15) 0.397 0.98 (0.85-1.13) 0.437
* Number of comparisons
† Random-effects model was used when P value for heterogeneity test < 0.05; otherwise, fix-effects model was used
‡ P value of Q-test for heterogeneity test
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morphism could influence the sensitivity to ionizing
radiation [50], it does not result in reduced endonu-
clease activity [18]. A previous meta-analysis which
investigated the association of 1349 T > G polymorph-
ism and cancer risk suggested that the variant genotypes
were associated with a moderately increased risk of all
cancer types (OR = 1.09, 95% CI = 1.01-1.18 for TG
versus TT; OR = 1.08, 95% CI = 1.00-1.18 for GG/TG
versus TT) [51]. Compared with the previous study, we
excluded four studies [46,52-54] in which the 1349 T >
G genotype distributions in controls did not conform to
HWE, since deviations fromH W Ei nc o n t r o ls u b j e c t s
may bias the estimates of genetic effects in genetic asso-
ciation studies and meta-analysis. Besides, four addi-
tional studies with 2, 307 cases and 3, 184 control
subjects in total were included in the present meta-ana-
lysis which could provide more solid evidence on the
specific lack of association between APE1 1349 T > G
polymorphism and cancer risk.. Given the power of this
meta-analysis which included 14,740 cases and 20,533
controls, a false-negative finding is unlikely. However,
further studies may be still needed to investigate the
interactions between APE1 polymorphism and environ-
mental factors which play important role in carcinogen-
esis but were not assessed in the present meta-analysis
due to lack of original data. Besides, more attention
drew to the prospective −656 T > G polymorphism in
the further studies may be helpful to reveal the role of
APE1 in the etiology of cancer.
Some limitations of our meta-analysis should be
addressed. Firstly, the numbers of published studies col-
lected in our analysis were not large enough for the
comprehensive analysis, especially for the APE1 −656 T
> G polymorphism. Secondly, lacking the original data
of the included studies limited our study to further eval-
uate the potential interactions, since gene-environment
and gene-gene interactions and even different poly-
morphic loci of the same gene may also modulate can-
cer risk. Besides, our results were based on unadjusted
estimates, while a more precise analysis needs to be
conducted if individual data such as age and sex are
available. Nevertheless, advantages in our meta-analysis
should also be acknowledged. First, a systematic review
of the association of APE1 polymorphisms with cancer
risk is statistically more powerful than any single study.
Figure 1 Meta-analysis with a random-effects model for the
association between cancer risk and the APE1 −656 T > G
polymorphism stratified by ethnicity (TG/GG vs. TT). OR, odds
ratio; CI, confidence interval; I-squared, measure to quantify the
degree of heterogeneity in meta-analyses.
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Figure 2 Meta-analysis with a random-effects model for the
association between cancer risk and the APE1 -656 T > G
polymorphism stratified by cancer types (TG/GG vs. TT). OR,
odds ratio; CI, confidence interval; I-squared, measure to quantify
the degree of heterogeneity in meta-analyses.
Begg's funnel plot with pseudo 95% confidence limits
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Figure 3 Begg’s funnel plot of publication bias test (−656 T >
G; GG vs. TT/TG). Each point represents a separate study for the
indicated association. Log (OR), natural logarithm of OR; Horizontal
line, mean effect size.
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and satisfactory met our selection criteria.
Conclusions
In conclusion, the results from this meta-analysis sug-
gest that the APE1 −656 T > G polymorphism, but not
the APE1 1349 T > G polymorphism may contribute to
genetic susceptibility to cancer. Further prospective stu-
dies with larger numbers of unbiased-matched homoge-
neous patients and well-matched controls are required
to validate our results and to clarify the gene-gene and
gene-environment interactions between APE1 poly-
morphisms and cancer risk.
Author details
1Department of General Surgery, Jiangyin People’s Hospital, South-East
University, Jiangyin, China.
2Department of Oncology, Jiangyin People’s
Hospital, South-East University, Jiangyin, China.
3Department of General
Surgery, Jiangyin People’s Hospital, 163 Shoushan Road, Jiangyin 214400,
China.
Authors’ contributions
BZ carries out the meta-analysis study and drafted the manuscript. HS
participates in the design of the study and performs the statistical analysis.
YS and KX collect and extract the data. XS and WM have been involved in
revising the manuscript critically for important intellectual content. QS
conceives of the study, and participates in its design and coordination and
helps to draft the manuscript. All authors read and approve the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 30 June 2011 Accepted: 18 December 2011
Published: 18 December 2011
References
1. Pharoah PD, Dunning AM, Ponder BA, Easton DF: Association studies for
finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004,
4(11):850-860.
2. Iscovich J, Howe GR: Cancer incidence patterns (1972-91) among
migrants from the Soviet Union to Israel. Cancer Causes Control 1998,
9(1):29-36.
3. Hecht SS: Cigarette smoking and lung cancer: chemical mechanisms and
approaches to prevention. Lancet Oncol 2002, 3(8):461-469.
4. Hoeijmakers JH: Genome maintenance mechanisms for preventing
cancer. Nature 2001, 411(6835):366-374.
5. Barzilay G, Hickson ID: Structure and function of apurinic/apyrimidinic
endonucleases. Bioessays 1995, 17(8):713-719.
6. Tell G, Quadrifoglio F, Tiribelli C, Kelley MR: The many functions of APE1/
Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal 2009,
11(3):601-620.
7. Izumi T, Hazra TK, Boldogh I, Tomkinson AE, Park MS, Ikeda S, Mitra S:
Requirement for human AP endonuclease 1 for repair of 3’-blocking
damage at DNA single-strand breaks induced by reactive oxygen
species. Carcinogenesis 2000, 21(7):1329-1334.
8. Fortini P, Pascucci B, Parlanti E, D’Errico M, Simonelli V, Dogliotti E: The base
excision repair: mechanisms and its relevance for cancer susceptibility.
Biochimie 2003, 85(11):1053-1071.
9. Bhakat KK, Mantha AK, Mitra S: Transcriptional regulatory functions of
mammalian AP-endonuclease (APE1/Ref-1), an essential multifunctional
protein. Antioxid Redox Signal 2009, 11(3):621-638.
10. Tell G, Fantini D, Quadrifoglio F: Understanding different functions of
mammalian AP endonuclease (APE1) as a promising tool for cancer
treatment. Cell Mol Life Sci 2010, 67(21):3589-3608.
11. Xi T, Jones IM, Mohrenweiser HW: Many amino acid substitution variants
identified in DNA repair genes during human population screenings are
predicted to impact protein function. Genomics 2004, 83(6):970-979.
12. Lu J, Zhang S, Chen D, Wang H, Wu W, Wang X, Lei Y, Wang J, Qian J,
Fan W, et al: Functional characterization of a promoter polymorphism in
APE1/Ref-1 that contributes to reduced lung cancer susceptibility. FASEB
J 2009, 23(10):3459-3469.
13. Lo YL, Jou YS, Hsiao CF, Chang GC, Tsai YH, Su WC, Chen KY, Chen YM,
Huang MS, Hu CY, et al: A polymorphism in the APE1 gene promoter is
associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2009,
18(1):223-229.
Table 3 Meta-analysis of the APE1 1349 T > G polymorphism and cancer risk
Variables n * GG vs. TT TG vs. TT GG/TG vs. TT GG vs. TT/TG
OR (95% CI)
† P
‡ OR (95% CI)
† P
‡ OR (95% CI)
† P
‡ OR (95% CI)
† P
‡
Total 35 1.05 (0.95-1.16) 0.001 1.04 (0.96-1.12) 0.004 1.04 (0.97-1.13) 0.000 1.03 (0.96-1.11) 0.022
Ethnicities
Asian 10 1.05 (0.93-1.20) 0.051 0.97 (0.88-1.07) 0.657 0.99 (0.90-1.08) 0.427 1.08 (0.92-1.28) 0.035
European 23 1.05 (0.92-1.19) 0.001 1.09 (0.99-1.20) 0.003 1.09 (0.98-1.21) 0.000 1.00 (0.94-1.07) 0.062
Source of controls
Population-based 15 1.01 (0.92-1.11) 0.130 1.07 (0.95-1.21) 0.010 1.06 (094-1.20) 0.004 0.98 (0.90-1.07) 0.335
Hospital-based 20 1.07 (0.92-1.24) 0.000 1.02 (0.93-1.11) 0.048 1.03 (0.93-1.15) 0.002 1.06 (0.95-1.20) 0.014
Cancer types
Lung cancer 9 1.08 (0.85-1.38) 0.017 0.99 (0.84-1.17) 0.059 1.03 (0.85-1.25) 0.007 1.04 (0.92-1.19) 0.086
Bladder cancer 7 0.96 (0.83-1.09) 0.312 1.01 (0.91-1.12) 0.376 0.99 (0.90-1.10) 0.453 0.95 (0.85-1.07) 0.360
Colorectal cancer 4 0.93 (0.55-1.57) 0.001 1.05 (0.78-1.41) 0.025 1.01 (0.72-1.43) 0.003 0.93 (0.63-1.39) 0.003
Breast cancer 4 1.20 (0.82-1.76) 0.042 1.19 (0.76-1.86) 0.000 1.23 (0.79-1.92) 0.000 1.06 (0.92-1.23) 0.345
Head and neck cancer 2 1.03 (0.80-1.32) 0.306 1.00 (0.81-1.23) 0.242 1.01 (0.83-1.23) 0.202 1.03 (0.83-1.27) 0.621
Others 9 1.07 (0.94-1.23) 0.156 1.05 (0.94-1.16) 0.754 1.05 (0.96-1.16) 0.609 1.05 (0.93-1.18) 0.111
* Number of comparisons
† Random-effects model was used when P value for heterogeneity test <0.05; otherwise, fix-effects model was used
‡ P value of Q-test for heterogeneity test
Zhou et al. BMC Cancer 2011, 11:521
http://www.biomedcentral.com/1471-2407/11/521
Page 7 of 914. Wang M, Qin C, Zhu J, Yuan L, Fu G, Zhang Z, Yin C: Genetic variants of
XRCC1, APE1, and ADPRT genes and risk of bladder cancer. DNA Cell Biol
2010, 29(6):303-311.
15. Zhou K, Hu D, Lu J, Fan W, Liu H, Chen H, Chen G, Wei Q, Du G, Mao Y,
et al: A genetic variant in the APE1/Ref-1 gene promoter -141 T/G may
modulate risk of glioblastoma in a Chinese Han population. BMC Cancer
2011, 11:104.
16. Berndt SI, Huang WY, Fallin MD, Helzlsouer KJ, Platz EA, Weissfeld JL,
Church TR, Welch R, Chanock SJ, Hayes RB: Genetic variation in base
excision repair genes and the prevalence of advanced colorectal
adenoma. Cancer Res 2007, 67(3):1395-1404.
17. Figueroa JD, Malats N, Real FX, Silverman D, Kogevinas M, Chanock S,
Welch R, Dosemeci M, Tardon A, Serra C, et al: Genetic variation in the
base excision repair pathway and bladder cancer risk. Hum Genet 2007,
121(2):233-242.
18. Hadi MZ, Coleman MA, Fidelis K, Mohrenweiser HW, Wilson DM: Functional
characterization of Ape1 variants identified in the human population.
Nucleic Acids Res 2000, 28(20):3871-3879.
19. Au WW, Salama SA, Sierra-Torres CH: Functional characterization of
polymorphisms in DNA repair genes using cytogenetic challenge assays.
Environ Health Perspect 2003, 111(15):1843-1850.
20. Mantel N, Haenszel W: Statistical aspects of the analysis of data from
retrospective studies of disease. J Natl Cancer Inst 1959, 22(4):719-748.
21. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials
1986, 7(3):177-188.
22. Mitra AK, Singh N, Singh A, Garg VK, Agarwal A, Sharma M, Chaturvedi R,
Rath SK: Association of polymorphisms in base excision repair genes
with the risk of breast cancer: a case-control study in North Indian
women. Oncol Res 2008, 17(3):127-135.
23. Misra RR, Ratnasinghe D, Tangrea JA, Virtamo J, Andersen MR, Barrett M,
Taylor PR, Albanes D: Polymorphisms in the DNA repair genes XPD,
XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male
smokers in Finland. Cancer Lett 2003, 191(2):171-178.
24. Popanda O, Schattenberg T, Phong CT, Butkiewicz D, Risch A, Edler L,
Kayser K, Dienemann H, Schulz V, Drings P, et al: Specific combinations of
DNA repair gene variants and increased risk for non-small cell lung
cancer. Carcinogenesis 2004, 25(12):2433-2441.
25. Hao B, Wang H, Zhou K, Li Y, Chen X, Zhou G, Zhu Y, Miao X, Tan W,
Wei Q, et al: Identification of genetic variants in base excision repair
pathway and their associations with risk of esophageal squamous cell
carcinoma. Cancer Res 2004, 64(12):4378-4384.
26. Ito H, Matsuo K, Hamajima N, Mitsudomi T, Sugiura T, Saito T, Yasue T,
Lee KM, Kang D, Yoo KY, et al: Gene-environment interactions between
the smoking habit and polymorphisms in the DNA repair genes, APE1
Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk.
Carcinogenesis 2004, 25(8):1395-1401.
27. Shen M, Berndt SI, Rothman N, Mumford JL, He X, Yeager M, Welch R,
Chanock S, Keohavong P, Donahue M, et al: Polymorphisms in the DNA
base excision repair genes APEX1 and XRCC1 and lung cancer risk in
Xuan Wei, China. Anticancer Res 2005, 25(1B):537-542.
28. Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I,
Gonzalez S, Guino E, Capella G, Canzian F: Polymorphisms in genes of
nucleotide and base excision repair: risk and prognosis of colorectal
cancer. Clin Cancer Res 2006, 12(7 Pt 1):2101-2108.
29. Jiao L, Bondy ML, Hassan MM, Wolff RA, Evans DB, Abbruzzese JL, Li D:
Selected polymorphisms of DNA repair genes and risk of pancreatic
cancer. Cancer Detect Prev 2006, 30(3):284-291.
30. Terry PD, Umbach DM, Taylor JA: APE1 genotype and risk of bladder
cancer: evidence for effect modification by smoking. Int J Cancer 2006,
118(12):3170-3173.
31. Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, Zhang Q, Millikan RE,
Lerner S, Dinney CP, et al: Bladder cancer predisposition: a multigenic
approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet
2006, 78(3):464-479.
32. Zhang Y, Newcomb PA, Egan KM, Titus-Ernstoff L, Chanock S, Welch R,
Brinton LA, Lissowska J, Bardin-Mikolajczak A, Peplonska B, et al: Genetic
polymorphisms in base-excision repair pathway genes and risk of breast
cancer. Cancer Epidemiol Biomarkers Prev 2006, 15(2):353-358.
33. Matullo G, Dunning AM, Guarrera S, Baynes C, Polidoro S, Garte S, Autrup H,
Malaveille C, Peluso M, Airoldi L, et al: DNA repair polymorphisms and
cancer risk in non-smokers in a cohort study. Carcinogenesis 2006,
27(5):997-1007.
34. Chen L, Ambrosone CB, Lee J, Sellers TA, Pow-Sang J, Park JY: Association
between polymorphisms in the DNA repair genes XRCC1 and APE1, and
the risk of prostate cancer in white and black Americans. J Urol 2006,
175(1):108-112, discussion 112.
35. Li C, Hu Z, Lu J, Liu Z, Wang LE, El-Naggar AK, Sturgis EM, Spitz MR, Wei Q:
Genetic polymorphisms in DNA base-excision repair genes ADPRT,
XRCC1, and APE1 and the risk of squamous cell carcinoma of the head
and neck. Cancer 2007, 110(4):867-875.
36. Andrew AS, Karagas MR, Nelson HH, Guarrera S, Polidoro S, Gamberini S,
Sacerdote C, Moore JH, Kelsey KT, Demidenko E, et al: DNA repair
polymorphisms modify bladder cancer risk: a multi-factor analytic
strategy. Hum Hered 2008, 65(2):105-118.
37. Pardini B, Naccarati A, Novotny J, Smerhovsky Z, Vodickova L, Polakova V,
Hanova M, Slyskova J, Tulupova E, Kumar R, et al: DNA repair genetic
polymorphisms and risk of colorectal cancer in the Czech Republic.
Mutat Res 2008, 638(1-2):146-153.
38. Tse D, Zhai R, Zhou W, Heist RS, Asomaning K, Su L, Lynch TJ, Wain JC,
Christiani DC, Liu G: Polymorphisms of the NER pathway genes, ERCC1
and XPD are associated with esophageal adenocarcinoma risk. Cancer
Causes Control 2008, 19(10):1077-1083.
39. Huang WY, Gao YT, Rashid A, Sakoda LC, Deng J, Shen MC, Wang BS,
Han TQ, Zhang BH, Chen BE, et al: Selected base excision repair gene
polymorphisms and susceptibility to biliary tract cancer and biliary
stones: a population-based case-control study in China. Carcinogenesis
2008, 29(1):100-105.
40. Chiang FY, Wu CW, Hsiao PJ, Kuo WR, Lee KW, Lin JC, Liao YC, Juo SH:
Association between polymorphisms in DNA base excision repair genes
XRCC1, APE1, and ADPRT and differentiated thyroid carcinoma. Clin
Cancer Res 2008, 14(18):5919-5924.
41. Smith TR, Levine EA, Freimanis RI, Akman SA, Allen GO, Hoang KN, Liu-
Mares W, Hu JJ: Polygenic model of DNA repair genetic polymorphisms
in human breast cancer risk. Carcinogenesis 2008, 29(11):2132-2138.
42. Gangwar R, Ahirwar D, Mandhani A, Mittal RD: Influence of XPD and APE1
DNA repair gene polymorphism on bladder cancer susceptibility in
north India. Urology 2009, 73(3):675-680.
43. Agachan B, Kucukhuseyin O, Aksoy P, Turna A, Yaylim I, Gormus U, Ergen A,
Zeybek U, Dalan B, Isbir T: Apurinic/apyrimidinic endonuclease (APE1)
gene polymorphisms and lung cancer risk in relation to tobacco
smoking. Anticancer Res 2009, 29(6):2417-2420.
44. Deng Q, Sheng L, Su D, Zhang L, Liu P, Lu K, Ma S: Genetic
polymorphisms in ATM, ERCC1, APE1 and iASPP genes and lung cancer
risk in a population of southeast China. Med Oncol 2011, 28(3):667-672.
45. Palli D, Polidoro S, D’Errico M, Saieva C, Guarrera S, Calcagnile AS, Sera F,
Allione A, Gemma S, Zanna I, et al: Polymorphic DNA repair and
metabolic genes: a multigenic study on gastric cancer. Mutagenesis 2010,
25(6):569-575.
46. Jelonek K, Gdowicz-Klosok A, Pietrowska M, Borkowska M, Korfanty J,
Rzeszowska-Wolny J, Widlak P: Association between single-nucleotide
polymorphisms of selected genes involved in the response to DNA
damage and risk of colon, head and neck, and breast cancers in a
Polish population. J Appl Genet 2010, 51(3):343-352.
47. Cao Q, Qin C, Meng X, Ju X, Ding Q, Wang M, Zhu J, Wang W, Li P, Chen J,
et al: Genetic polymorphisms in APE1 are associated with renal cell
carcinoma risk in a chinese population. Mol Carcinog 2011,
50(11):863-870.
48. Duval S, Tweedie R: Trim and fill: A simple funnel-plot-based method of
testing and adjusting for publication bias in meta-analysis. Biometrics
2000, 56(2):455-463.
49. Lindahl T: Recognition and processing of damaged DNA. J Cell Sci Suppl
1995, 19:73-77.
50. Hu JJ, Smith TR, Miller MS, Lohman K, Case LD: Genetic regulation of
ionizing radiation sensitivity and breast cancer risk. Environ Mol Mutagen
2002, 39(2-3):208-215.
51. Gu D, Wang M, Zhang Z, Chen J: The DNA repair gene APE1 T1349G
polymorphism and cancer risk: a meta-analysis of 27 case-control
studies. Mutagenesis 2009, 24(6):507-512.
52. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L,
Phillips DH, Canzian F, Haugen A: Polymorphisms of DNA repair genes
and risk of non-small cell lung cancer. Carcinogenesis 2006, 27(3):560-567.
Zhou et al. BMC Cancer 2011, 11:521
http://www.biomedcentral.com/1471-2407/11/521
Page 8 of 953. De Ruyck K, Szaumkessel M, De Rudder I, Dehoorne A, Vral A, Claes K,
Velghe A, Van Meerbeeck J, Thierens H: Polymorphisms in base-excision
repair and nucleotide-excision repair genes in relation to lung cancer
risk. Mutat Res 2007, 631(2):101-110.
54. Canbay E, Agachan B, Gulluoglu M, Isbir T, Balik E, Yamaner S, Bulut T,
Cacina C, Eraltan IY, Yilmaz A, et al: Possible associations of APE1
polymorphism with susceptibility and HOGG1 polymorphism with
prognosis in gastric cancer. Anticancer Res 2010, 30(4):1359-1364.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/521/prepub
doi:10.1186/1471-2407-11-521
Cite this article as: Zhou et al.: The association of APE1 −656T > G and
1349 T > G polymorphisms and cancer risk: a meta-analysis based on
37 case-control studies. BMC Cancer 2011 11:521.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zhou et al. BMC Cancer 2011, 11:521
http://www.biomedcentral.com/1471-2407/11/521
Page 9 of 9